Charles Schwab Investment Management Inc Cardiff Oncology, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 189,315 shares of CRDF stock, worth $425,958. This represents 0.0% of its overall portfolio holdings.
Number of Shares
189,315
Previous 169,974
11.38%
Holding current value
$425,958
Previous $533,000
11.82%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CRDF
# of Institutions
126Shares Held
26.4MCall Options Held
1.01MPut Options Held
293K-
Vanguard Group Inc Valley Forge, PA3.73MShares$8.39 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$5.91 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.52MShares$5.68 Million0.02% of portfolio
-
Laurion Capital Management LP New York, NY1.8MShares$4.04 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA1.5MShares$3.37 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $97.5M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...